North China Pharmaceutical gains approval for vitamin B6 injection

North China Pharmaceutical (SSE:600812) announced it has received the "Notice of Approval of Supplementary Drug Application" from the National Medical Products Administration for its Vitamin B6 injection (1ml: 100mg), alongside registration for Isavuconazonium Sulfate. The Vitamin B6 injection approval includes the addition of the 1ml:100mg specification and confirms the product's bioequivalence with original formulations. The company already has a 1ml: 50mg version of the Vitamin B6 Injection approved in 2004. For the Isavuconazonium Sulfate (0.2g) product, this approval positions North China Pharmaceutical among a limited number of domestic manufacturers. The company invested CNY 14.77 million and CNY 15.27 million in R&D for Vitamin B6 injection and Isavuconazonium Sulfate respectively. While the addition of the Vitamin B6 injection specification and Isavuconazonium Sulfate are expected to enhance North China Pharmaceutical's product offerings, the company cautions investors about potential risks from evolving industry policies and market conditions.